By hosting "R&D Dating for Animal Health", BioFIT succeeds in creating the main event for the innovators of the concept of “One Health” and for the development of public-private partnerships.

For us, BioFIT is one node in the innovation network at the European level and we are proud to know that it is a French node that is really efficient. It's bringing together the Human Health, initially it was mostly human health, and more and more we are seeing animal health companies participating in that event. It's one place with human and animal health and our objective is to highlight the bridges that you can find between animal and human health. We are also here to learn to human health companies that working with us will help them, and to highlight the synergies we have by working together.

BioFIT is definitely one of the main gatherings in our field in Europe and it is very important for us to know the partners and the companies that operate in Europe, that we can work with, that are looking for services. But mainly, we are looking for partners that are looking to in-license technologies. We tend to come to these meetings such as BioFIT because we know the market and we need to know who we would like to work with in the next stage.

Winning the BioFIT 'Collaborative and Licensing Opportunity' award was very exciting for Brenus Pharma's team! The jury's insightful questions helped us getting further in the presentation of our Stimulated Ghost Cells technology. With our clinical trial launching next quarter, we're eager to demonstrate safety data and open doors to partnerships exploring combinations with therapies such as checkpoint inhibitors and antibody-drug conjugates. BioFIT gave us the platform we needed at this critical stage.